Is Self-Affirming GRAS Off the Menu?

March 12, 2025

Reading Time : 2 min

United States Department of Health and Human Services (HHS) Secretary Kennedy recently directed the U.S. Food and Drug Administration (FDA) to consider rulemaking to revise its longstanding regulations and guidance governing the oversight of food ingredients to eliminate the ability of individuals and companies to self-affirm that their ingredients are Generally Recognized as Safe (GRAS). This would mark a massive shift in how new food ingredients are introduced to the market.

In 1958, Congress enacted the Food Additives Amendment to the Food, Drug and Cosmetic Act (FDCA). These amendments required that “food additives” receive premarket approval from FDA, unless they were “substances that are generally recognized, among experts qualified by scientific training and experience to evaluate their safety as having been adequately shown… to be safe under the conditions of their intended use.” Such substances are considered to be “generally recognized as safe”.[1]

The agency’s approach to GRAS determinations has evolved over the intervening decades, with the last major change coming in 2016 with the publication of what is referred to as the final GRAS rule. Under this rule, “any person may notify FDA of a view that a substance is not subject to the premarket approval requirements….” 21 C.F.R. § 170.205. This provision establishes a voluntary pathway for industry to submit a GRAS notification to FDA—in other words, a person or company may make an “independent conclusion of GRAS status” without also making a submission to FDA (though FDA strongly encourages submitting notice to the agency for review).[2]This process, otherwise known as “self-affirming,” is the subject of Secretary Kennedy’s order.  

In his order, Secretary Kennedy states that “[f]or far too long, ingredient manufacturers and sponsors have exploited a loophole that has allowed new ingredients and chemicals, often with unknown safety data, to be introduced into the U.S. food supply without notification to the FDA or the public… Eliminating this loophole will provide transparency to consumers, [and] help get our nation’s food supply back on track….” Further still, the order notes that HHS is “committed to working with Congress to explore ways legislation can completely close the GRAS loophole.”

While details are sparse, removal of the self-affirming pathway would presumably require rulemaking or legislation. In the interim, FDA could start exercising greater scrutiny of self-affirming GRAS determinations. An end to the self-affirmation process would also create significantly more work for the agency in evaluating proposed new ingredients, at a time when the administration is attempting to drastically shrink the FDA work force.


[1] Note that substances used in food before 1958 may also be considered GRAS based on a determination made through experience based on common use in food. 21 C.F. R. § 170.30.

[2] 81 Fed. Reg. 54,960, 54,966 (Aug. 17, 2016).

Share This Insight

Previous Entries

Eye on FDA

February 17, 2026

On February 3, 2026, the Consolidated Appropriations Act, 2026 (P.L. 119-75) became law and marked an important milestone in the bipartisan congressional effort to reauthorize the rare pediatric disease priority review voucher program. Section 6604 of this law extends the Food and Drug Administration’s (FDA) authority to issue priority review vouchers to encourage treatments for rare pediatric diseases through September 30, 2029.

...

Read More

Eye on FDA

February 17, 2026

In case you missed it, Department of Health and Human Services Secretary Robert F. Kennedy Jr. and former Food and Drug Administration (FDA) Commissioner David Kessler appeared on 60 Minutes this past Saturday, February 15, in a segment titled “Generally Recognized as Safe.” As the title suggests, the conversation centered on FDA’s Generally Recognized as Safe (GRAS) regulatory pathway (for background, see our prior post discussing in more detail the GRAS process), as well as Commissioner Kessler’s August 2025 citizen petition urging FDA to revoke the GRAS status of refined carbohydrates used in industrial food processing (discussed in more detail in our earlier coverage of the petition).

...

Read More

Eye on FDA

February 3, 2026

On February 1, 2026, the Food and Drug Administration (FDA) officially started accepting requests to participate in the FDA PreCheck pilot program. The goal of the program is to strengthen the domestic pharmaceutical supply chain by making the review and inspection process more predictable for U.S.-based drug manufacturing facilities.

...

Read More

Eye on FDA

January 28, 2026

The Food and Drug Administration (FDA) has begun 2026 with a clear signal to the direct‑to‑consumer testing industry: self‑collection devices remain firmly within the agency’s regulatory reach, notwithstanding the 2025 court ruling on laboratory developed tests (LDTs). Last week, the agency published warning letters previously issued to four companies—Genetrace, Genovate, Germaphobix and ProDx Health—selling human immunodeficiency virus (HIV) tests that rely on unauthorized self‑collection kits.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.